Schumer Includes Cannabinoid Pathway For Supplements In Cannabis Legalization Draft Bill
Joined by Wyden And Booker, Majority Leader Also Proposes Setting Safe Daily Level
Draft bill proposes rules not only on producing and marketing marijuana, but on using in supplements ingredients derived from cannabis plants classified as hemp. Some supplement industry stakeholders see draft as delivering on industry requests but others say it goes too far.
You may also be interested in...
CBD Will Be US FDA’s ‘One’ Lawful Hemp Compound, House Appropriators Anticipate
Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.
Cannabinoids Are Test Case For US FDA Advisors’ ‘Predicted Pharmacological Activity’ Discussion
Busy agenda of disparate topics in one-day meeting likely valuable for informing FDA on safety of hemp ingredients but not for moving toward a regulatory pathway for the ingredients' lawful use in supplements and food.
US Cannabis Legalization Cultivated By House Has Thorny Forecast For Harvest In Senate
Absence of hemp provisions in House bill could be a problem with Senate Democrats, who have drafted legislation not only on producing, marketing and possessing marijuana but also using in supplements ingredients classified as hemp. Still, Senate passage of cannabis legalization is unlikely.